Published in Transplantation on October 27, 2007
Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol (2010) 2.42
Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol (2010) 1.87
Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle (2007) 1.15
Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients. Am J Transplant (2012) 1.06
BAFF is increased in renal transplant patients following treatment with alemtuzumab. Am J Transplant (2009) 1.06
Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol (2011) 1.04
B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells. Am J Transplant (2012) 1.03
Regulatory T cell induction, migration, and function in transplantation. J Immunol (2012) 0.96
Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo. Am J Transplant (2012) 0.91
Is it time to give up with calcineurin inhibitors in kidney transplantation? World J Transplant (2013) 0.86
Inducing and Administering Tregs to Treat Human Disease. Front Immunol (2016) 0.84
Differential targeting of IL-2 and T cell receptor signaling pathways selectively expands regulatory T cells while inhibiting conventional T cells. J Autoimmun (2013) 0.83
Monitoring of CD4+CD25highIL-7Rαhigh activated T cells in kidney transplant recipients. Clin J Am Soc Nephrol (2011) 0.80
The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients. Transplantation (2016) 0.79
The Microbiome, Systemic Immune Function, and Allotransplantation. Clin Microbiol Rev (2016) 0.79
Noninvasive methods to assess the risk of kidney transplant rejection. Expert Rev Clin Immunol (2009) 0.78
Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. BMC Cancer (2011) 0.78
Transplantation: time to rethink immunosuppression by mTOR inhibitors? Nat Rev Nephrol (2009) 0.78
Impact of Immune-Modulatory Drugs on Regulatory T Cell. Transplantation (2016) 0.77
The evolving role of alemtuzumab (Campath-1H) in renal transplantation. Drug Des Devel Ther (2009) 0.76
Differential sensitivity of regulatory and effector T cells to cell death: a prerequisite for transplant tolerance. Front Immunol (2015) 0.75
Monitoring alloimmune response in kidney transplantation. J Nephrol (2016) 0.75
Lymphocyte Activation Markers in Pediatric Kidney Transplant Recipients. Int J Biomed Sci (2015) 0.75
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet (2012) 11.32
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int (2009) 7.45
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int (2009) 7.19
Preventing microalbuminuria in type 2 diabetes. N Engl J Med (2004) 6.41
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int (2011) 6.21
Atypical hemolytic-uremic syndrome. N Engl J Med (2009) 5.66
Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest (2005) 5.51
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Long-term outcome of renal transplantation from older donors. N Engl J Med (2006) 5.10
A multicentre, randomised, open-label, controlled trial evaluating equivalence of inhalational and intravenous anaesthesia during elective craniotomy. Eur J Anaesthesiol (2012) 4.73
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol (2012) 3.79
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet (2005) 3.52
How does proteinuria cause progressive renal damage? J Am Soc Nephrol (2006) 3.46
Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol (2004) 3.41
Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.24
The Ngal reporter mouse detects the response of the kidney to injury in real time. Nat Med (2011) 3.20
Hemolytic uremic syndrome. J Am Soc Nephrol (2005) 3.19
Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med (2011) 3.17
Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol (2011) 3.13
Delayed graft function in kidney transplantation. Lancet (2004) 3.06
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest (2003) 2.96
Decision time for pancreatic islet-cell transplantation. Lancet (2008) 2.91
Familial haemolytic uraemic syndrome and an MCP mutation. Lancet (2003) 2.79
Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet (2003) 2.71
Renal progenitors: an evolutionary conserved strategy for kidney regeneration. Nat Rev Nephrol (2013) 2.66
MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med (2011) 2.65
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol (2011) 2.60
Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells (2008) 2.51
Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest (2009) 2.49
Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol (2008) 2.48
Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis (2004) 2.43
Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol (2010) 2.42
Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet (2004) 2.38
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol (2007) 2.37
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int (2005) 2.32
MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition. J Am Soc Nephrol (2012) 2.26
Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-L-carnitine therapy. Hypertension (2009) 2.20
Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol (2008) 2.17
Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis (2006) 2.17
The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int (2010) 2.14
Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes (2002) 2.12
Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet (2002) 2.12
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens (2007) 2.12
The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl (2005) 2.10
Rituximab for idiopathic membranous nephropathy. Lancet (2002) 2.03
Insulin-like growth factor-1 sustains stem cell mediated renal repair. J Am Soc Nephrol (2007) 2.02
Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol (2007) 2.00
Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol (2008) 1.99
Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem (2008) 1.97
Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl (2005) 1.96